This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Synimmune Gmbh. Active years: 2015.
Company Filing History:
Years Active: 2015
Title: Steffen Aulwurm: Innovator in Anti-FLT3 Antibodies
Introduction
Steffen Aulwurm is a notable inventor based in Hechingen, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. His work focuses on enhancing the efficacy of these antibodies for medical applications.
Latest Patents
Steffen Aulwurm holds 1 patent related to anti-FLT3 antibodies. This invention involves antibodies with a modified Fc region that includes the amino acid substitutions 239D and 332E. These modifications are designed to enhance antibody-dependent cell cytotoxicity (ADCC). The patent also encompasses pharmaceutical compositions containing these antibodies, nucleic acids encoding them, and methods for their use.
Career Highlights
Aulwurm is associated with Synimmune GmbH, a company that specializes in the development of innovative antibody therapies. His work at Synimmune has positioned him as a key player in the biotechnology sector, contributing to advancements in cancer treatment.
Collaborations
Steffen Aulwurm has collaborated with notable colleagues, including Ludger Grosse-Hovest and Hans-Joerg Buehring. These collaborations have further enriched his research and development efforts in the field of therapeutic antibodies.
Conclusion
Steffen Aulwurm's contributions to the development of anti-FLT3 antibodies highlight his innovative spirit and dedication to advancing medical science. His work continues to pave the way for new therapeutic options in the treatment of diseases.